Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. Issue 5 (October 2013)

• Record Type: Journal Article
• Authors: Gugliotta, Gabriele; Castagnetti, Fausto; Fogli, Miriam; Cavo, Michele; Baccarani, Michele; Rosti, Gianantonio
• Is Part Of: Expert review of hematology. Volume 6:Issue 5(2013)
• Page Start: 563
• Page End: 574
• Publication Date: 2013-10
• Subjects: age -- chronic myeloid leukemia -- comorbidity -- dasatinib -- elderly -- imatinib -- nilotinib -- tyrosine kinase inhibitors; Hematology -- Periodicals; 616.15005
• DOI: 10.1586/17474086.2013.837279
• Languages: English
• ISSNs: 1747-4086

Abstract

The median age at diagnosis of chronic myeloid leukemia (CML) is between 60 and 65 years in most epidemiologic registries. Rather than age per se, a comprehensive evaluation of comorbidities may describe more properly the general clinical status of a patient. Tyrosine-kinase inhibitors (TKIs) have a different tolerability profile, and some adverse events (AEs) are peculiar of each drug, in particular, in presence of predisposing factors (comorbidities, concomitant medications). This article will review the impact of comorbidities in the safety and outcome of CML patients treated with TKIs. We will explore how the comorbidity status may be considered, together with CML-related factors, in the selection of the TKI in order to optimize treatment.